Literature DB >> 20953243

The pathogenesis of prostate cancer: from molecular to metabolic alterations.

Elisa Benedettini1, Paul Nguyen, Massimo Loda.   

Abstract

Prostate cancer (PCa) is a heterogeneous disease with regard to molecular alterations and clinical course. The investigation of genetic alterations associated with PCa pathogenesis is highly challenging. Genome-wide analyses and epidemiological studies have identified only a handful of candidate genes possibly associated with hereditary or sporadic PCa. Cancer cells often rely for survival on common biochemical pathways such as enhanced anaerobic glycolysis and lipogenesis. The lipogenic enzyme fatty acid synthase seems to play a crucial part in PCa by conferring growth and survival advantages to cancer cells. We summarize the current understanding of the molecular events in PCa, and highlight the importance of altered lipid metabolism in the development and progression of prostate malignancy.

Entities:  

Year:  2008        PMID: 20953243      PMCID: PMC2955448          DOI: 10.1016/j.mpdhp.2008.03.001

Source DB:  PubMed          Journal:  Diagn Histopathol (Oxf)        ISSN: 1876-7621


  49 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

3.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Authors:  Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

4.  The isopeptidase USP2a protects human prostate cancer from apoptosis.

Authors:  Carmen Priolo; Dan Tang; Mohan Brahamandan; Barbara Benassi; Ewa Sicinska; Shuji Ogino; Antonella Farsetti; Alessandro Porrello; Stephen Finn; Johann Zimmermann; Phillip Febbo; Massimo Loda
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Authors:  Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

Review 6.  Pathological and molecular aspects of prostate cancer.

Authors:  Angelo M DeMarzo; William G Nelson; William B Isaacs; Jonathan I Epstein
Journal:  Lancet       Date:  2003-03-15       Impact factor: 79.321

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  Going malignant: the hypoxia-cancer connection in the prostate.

Authors:  P W Hochachka; J L Rupert; L Goldenberg; M Gleave; P Kozlowski
Journal:  Bioessays       Date:  2002-08       Impact factor: 4.345

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase.

Authors:  F P Kuhajda; E S Pizer; J N Li; N S Mani; G L Frehywot; C A Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  9 in total

1.  Quantitation of multiple sphingolipid classes using normal and reversed-phase LC-ESI-MS/MS: comparative profiling of two cell lines.

Authors:  M Athar Masood; Raghavendra P Rao; Jairaj K Acharya; Josip Blonder; Timothy D Veenstra
Journal:  Lipids       Date:  2011-11-29       Impact factor: 1.880

Review 2.  Metabolic alterations and targeted therapies in prostate cancer.

Authors:  Richard Flavin; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

3.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

4.  Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia.

Authors:  Juliana Lúcia de Albuquerque Vasconcelos; Steffany de Almeida Ferreira; Amanda Lucena Rosendo de Lima; Moacyr Jesus Barreto de Melo Rêgo; Ana Rosa Galdino Bandeira; Carmelita de Lima Bezerra Cavalcanti; Mariana Montenegro de Melo Lira; Eduardo Isidoro Carneiro Beltrão
Journal:  Acta Histochem Cytochem       Date:  2013-06-20       Impact factor: 1.938

5.  A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Authors:  Nelma Pertega-Gomes; Sergio Felisbino; Charlie E Massie; Jose R Vizcaino; Ricardo Coelho; Chiranjeevi Sandi; Susana Simoes-Sousa; Sarah Jurmeister; Antonio Ramos-Montoya; Mohammad Asim; Maxine Tran; Elsa Oliveira; Alexandre Lobo da Cunha; Valdemar Maximo; Fatima Baltazar; David E Neal; Lee G D Fryer
Journal:  J Pathol       Date:  2015-08       Impact factor: 7.996

6.  Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate.

Authors:  Rakesh K Pathak; Sean Marrache; Donald A Harn; Shanta Dhar
Journal:  ACS Chem Biol       Date:  2014-03-25       Impact factor: 5.100

7.  Proteomic Upregulation of Fatty Acid Synthase and Fatty Acid Binding Protein 5 and Identification of Cancer- and Race-Specific Pathway Associations in Human Prostate Cancer Tissues.

Authors:  Jennifer S Myers; Ariana K von Lersner; Qing-Xiang Amy Sang
Journal:  J Cancer       Date:  2016-07-05       Impact factor: 4.207

Review 8.  Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.

Authors:  Bartosz Malinowski; Michał Wiciński; Nikola Musiała; Ilona Osowska; Mateusz Szostak
Journal:  Diagnostics (Basel)       Date:  2019-10-25

9.  Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography.

Authors:  James M Kelly; Thomas M Jeitner; Nicole N Waterhouse; Wenchao Qu; Ethan J Linstad; Banafshe Samani; Clarence Williams; Anastasia Nikolopoulou; Alejandro Amor-Coarasa; Stephen G DiMagno; John W Babich
Journal:  Molecules       Date:  2022-02-25       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.